1
|
Surme S, Ergun C, Gul S, Akyel YK, Gul ZM, Ozcan O, Ipek OS, Akarlar BA, Ozlu N, Taskin AC, Turkay M, Gören AC, Baris I, Ozturk N, Guzel M, Aydin C, Okyar A, Kavakli IH. TW68, cryptochromes stabilizer, regulates fasting blood glucose levels in diabetic ob/ob and high fat-diet-induced obese mice. Biochem Pharmacol 2023; 218:115896. [PMID: 37898388 DOI: 10.1016/j.bcp.2023.115896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 10/30/2023]
Abstract
Cryptochromes (CRYs), transcriptional repressors of the circadian clock in mammals, inhibit cAMP production when glucagon activates G-protein coupled receptors. Therefore, molecules that modulate CRYs have the potential to regulate gluconeogenesis. In this study, we discovered a new molecule called TW68 that interacts with the primary pockets of mammalian CRY1/2, leading to reduced ubiquitination levels and increased stability. In cell-based circadian rhythm assays using U2OS Bmal1-dLuc cells, TW68 extended the period length of the circadian rhythm. Additionally, TW68 decreased the transcriptional levels of two genes, Phosphoenolpyruvate carboxykinase 1 (PCK1) and Glucose-6-phosphatase (G6PC), which play crucial roles in glucose biosynthesis during glucagon-induced gluconeogenesis in HepG2 cells. Oral administration of TW68 in mice showed good tolerance, a good pharmacokinetic profile, and remarkable bioavailability. Finally, when administered to fasting diabetic animals from ob/ob and HFD-fed obese mice, TW68 reduced blood glucose levels by enhancing CRY stabilization and subsequently decreasing the transcriptional levels of Pck1 and G6pc. These findings collectively demonstrate the antidiabetic efficacy of TW68 in vivo, suggesting its therapeutic potential for controlling fasting glucose levels in the treatment of type 2 diabetes mellitus.
Collapse
Affiliation(s)
- Saliha Surme
- Department of Molecular Biology and Genetics, Koc University, Rumelifeneri Yolu, Istanbul, Türkiye
| | - Cagla Ergun
- Department of Chemical and Biological Engineering, Koc University, Rumelifeneri Yolu, Istanbul, Türkiye
| | - Seref Gul
- Istanbul University, Department of Biology, Biotechnology Division, TR-34116 Beyazit-İstanbul, Türkiye; Current address: Bezmialem Vakif University, Institute of Life Sciences and Biotechnology, Beykoz, Istanbul, Türkiye
| | - Yasemin Kubra Akyel
- Istanbul Medipol University, School of Medicine, Department of Medical Pharmacology, İstanbul, Türkiye; Istanbul University, Faculty of Pharmacy Department of Pharmacology, TR-34116 Beyazit-İstanbul, Türkiye
| | - Zeynep Melis Gul
- Department of Molecular Biology and Genetics, Koc University, Rumelifeneri Yolu, Istanbul, Türkiye
| | - Onur Ozcan
- Department of Molecular Biology and Genetics, Koc University, Rumelifeneri Yolu, Istanbul, Türkiye
| | - Ozgecan Savlug Ipek
- Istanbul Medipol University, Regenerative and Restorative Medicine Research Center (REMER), Kavacik Campus, Kavacik-Beykoz/İstanbul 34810, Türkiye
| | - Busra Aytul Akarlar
- Department of Molecular Biology and Genetics, Koc University, Rumelifeneri Yolu, Istanbul, Türkiye
| | - Nurhan Ozlu
- Department of Molecular Biology and Genetics, Koc University, Rumelifeneri Yolu, Istanbul, Türkiye
| | - Ali Cihan Taskin
- Department of Laboratory Animal Science, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye
| | - Metin Turkay
- Department of Industrial Engineering, Koc University, Rumelifeneri Yolu, İstanbul, Türkiye
| | - Ahmet Ceyhan Gören
- Gebze Technical University, Department of Chemistry, Gebze, Kocaeli, Türkiye
| | - Ibrahim Baris
- Department of Molecular Biology and Genetics, Koc University, Rumelifeneri Yolu, Istanbul, Türkiye
| | - Nuri Ozturk
- Gebze Technical University, Department of Molecular Biology and Genetics, Gebze, Kocaeli, Türkiye
| | - Mustafa Guzel
- Istanbul Medipol University, Regenerative and Restorative Medicine Research Center (REMER), Kavacik Campus, Kavacik-Beykoz/İstanbul 34810, Türkiye
| | - Cihan Aydin
- Department of Molecular Biology and Genetics, Istanbul Medeniyet University, Istanbul, Türkiye
| | - Alper Okyar
- Istanbul University, Faculty of Pharmacy Department of Pharmacology, TR-34116 Beyazit-İstanbul, Türkiye
| | - Ibrahim Halil Kavakli
- Department of Molecular Biology and Genetics, Koc University, Rumelifeneri Yolu, Istanbul, Türkiye; Department of Chemical and Biological Engineering, Koc University, Rumelifeneri Yolu, Istanbul, Türkiye.
| |
Collapse
|
2
|
Gul S, Akyel YK, Gul ZM, Isin S, Ozcan O, Korkmaz T, Selvi S, Danis I, Ipek OS, Aygenli F, Taskin AC, Akarlar BA, Ozlu N, Ozturk N, Ozturk N, Ünal DÖ, Guzel M, Turkay M, Okyar A, Kavakli IH. Discovery of a small molecule that selectively destabilizes Cryptochrome 1 and enhances life span in p53 knockout mice. Nat Commun 2022; 13:6742. [PMID: 36347873 PMCID: PMC9643396 DOI: 10.1038/s41467-022-34582-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Accepted: 10/31/2022] [Indexed: 11/09/2022] Open
Abstract
Cryptochromes are negative transcriptional regulators of the circadian clock in mammals. It is not clear how reducing the level of endogenous CRY1 in mammals will affect circadian rhythm and the relation of such a decrease with apoptosis. Here, we discovered a molecule (M47) that destabilizes Cryptochrome 1 (CRY1) both in vitro and in vivo. The M47 selectively enhanced the degradation rate of CRY1 by increasing its ubiquitination and resulted in increasing the circadian period length of U2OS Bmal1-dLuc cells. In addition, subcellular fractionation studies from mice liver indicated that M47 increased degradation of the CRY1 in the nucleus. Furthermore, M47-mediated CRY1 reduction enhanced oxaliplatin-induced apoptosis in Ras-transformed p53 null fibroblast cells. Systemic repetitive administration of M47 increased the median lifespan of p53-/- mice by ~25%. Collectively our data suggest that M47 is a promising molecule to treat forms of cancer depending on the p53 mutation.
Collapse
Affiliation(s)
- Seref Gul
- grid.15876.3d0000000106887552Department of Chemical and Biological Engineering, Koc University, 34450 Sariyer-Istanbul, Turkey ,grid.9601.e0000 0001 2166 6619Present Address: Department of Biology, Biotechnology Division, İstanbul University, TR-34116 Beyazit-Istanbul, Turkey
| | - Yasemin Kubra Akyel
- grid.9601.e0000 0001 2166 6619Faculty of Pharmacy, Department of Pharmacology, İstanbul University, TR-34116 Beyazit-Istanbul, Turkey ,grid.411781.a0000 0004 0471 9346Present Address: School of Medicine, Department of Medical Pharmacology, Istanbul Medipol University, Istanbul, Turkey
| | - Zeynep Melis Gul
- grid.15876.3d0000000106887552Department of Molecular Biology and Genetics, Koc University, İstanbul, Turkey
| | - Safak Isin
- grid.15876.3d0000000106887552Department of Molecular Biology and Genetics, Koc University, İstanbul, Turkey
| | - Onur Ozcan
- grid.15876.3d0000000106887552Department of Molecular Biology and Genetics, Koc University, İstanbul, Turkey
| | - Tuba Korkmaz
- grid.448834.70000 0004 0595 7127Department of Molecular Biology and Genetics, Gebze Technical University, Gebze, 41400 Kocaeli, Turkey
| | - Saba Selvi
- grid.448834.70000 0004 0595 7127Department of Molecular Biology and Genetics, Gebze Technical University, Gebze, 41400 Kocaeli, Turkey
| | - Ibrahim Danis
- grid.9601.e0000 0001 2166 6619Faculty of Pharmacy, Department of Analytical Chemistry, İstanbul University, TR-34116 Beyazit-Istanbul, Turkey ,grid.9601.e0000 0001 2166 6619İstanbul University Drug Research and Application Center (ILAM), TR-34116 Beyazıt-Istanbul, Turkey
| | - Ozgecan Savlug Ipek
- grid.411781.a0000 0004 0471 9346Regenerative and Restorative Medicine Research Center (REMER), İstanbul Medipol University, Kavacik Campus, Kavacik-Beykoz/Istanbul, 34810 Turkey ,grid.38575.3c0000 0001 2337 3561Department of Chemistry, Graduate School of Natural and Applied Sciences, Yildiz Technical University, Besiktas/Istanbul, 34349 Turkey
| | - Fatih Aygenli
- grid.448834.70000 0004 0595 7127Department of Molecular Biology and Genetics, Gebze Technical University, Gebze, 41400 Kocaeli, Turkey
| | - Ali Cihan Taskin
- grid.15876.3d0000000106887552Animal Research Facility, Research Center for Translational Medicine, Koc University, Rumelifeneri yolu, 34450 Sariyer-Istanbul, Turkey
| | - Büşra Aytül Akarlar
- grid.15876.3d0000000106887552Department of Molecular Biology and Genetics, Koc University, İstanbul, Turkey
| | - Nurhan Ozlu
- grid.15876.3d0000000106887552Department of Molecular Biology and Genetics, Koc University, İstanbul, Turkey
| | - Nuri Ozturk
- grid.448834.70000 0004 0595 7127Department of Molecular Biology and Genetics, Gebze Technical University, Gebze, 41400 Kocaeli, Turkey
| | - Narin Ozturk
- grid.9601.e0000 0001 2166 6619Faculty of Pharmacy, Department of Pharmacology, İstanbul University, TR-34116 Beyazit-Istanbul, Turkey
| | - Durişehvar Özer Ünal
- grid.9601.e0000 0001 2166 6619Faculty of Pharmacy, Department of Analytical Chemistry, İstanbul University, TR-34116 Beyazit-Istanbul, Turkey ,grid.9601.e0000 0001 2166 6619İstanbul University Drug Research and Application Center (ILAM), TR-34116 Beyazıt-Istanbul, Turkey
| | - Mustafa Guzel
- grid.411781.a0000 0004 0471 9346Regenerative and Restorative Medicine Research Center (REMER), İstanbul Medipol University, Kavacik Campus, Kavacik-Beykoz/Istanbul, 34810 Turkey ,grid.411781.a0000 0004 0471 9346International School of Medicine, Department of Medical Pharmacology, Kavacik Campus, İstanbul Medipol University, Kavacik-Beykoz/Istanbul, 34810 Turkey
| | - Metin Turkay
- grid.15876.3d0000000106887552Department of Industrial Engineering, Koc University, Istanbul, Turkey
| | - Alper Okyar
- grid.9601.e0000 0001 2166 6619Faculty of Pharmacy, Department of Pharmacology, İstanbul University, TR-34116 Beyazit-Istanbul, Turkey
| | - Ibrahim Halil Kavakli
- grid.15876.3d0000000106887552Department of Chemical and Biological Engineering, Koc University, 34450 Sariyer-Istanbul, Turkey ,grid.15876.3d0000000106887552Department of Molecular Biology and Genetics, Koc University, İstanbul, Turkey
| |
Collapse
|
3
|
Sucu BO, Ipek OS, Kurtulus SO, Yazici BE, Karakas N, Guzel M. Synthesis of novel methyl jasmonate derivatives and evaluation of their biological activity in various cancer cell lines. Bioorg Chem 2019; 91:103146. [PMID: 31377389 DOI: 10.1016/j.bioorg.2019.103146] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Revised: 07/19/2019] [Accepted: 07/22/2019] [Indexed: 12/17/2022]
Abstract
Warburg hypothesized that the energy consumption of cancer cells is different than the normal cells. When compared to normal conditions, cancer cells do not undergo tricarboxylic acid (TCA) cycle therefore resulting in more lactate in the cells. Glycolysis pathway is a way of cancer cells to provide energy. The first step in glycolysis is the phosphorylation of glucose to glucose-6-phosphate. This reaction is catalyzed by the hexokinase-II enzyme (HK-II) which is known to be overexpressed in tumor cells. The feeding of cancer cells can be prevented by inhibiting the hexokinase-II enzyme in the first step of aerobic glycolysis. In literature, Methyl Jasmonate (MJ) is known as a Hexokinase-II inhibitor since it disposes VDAC and HK-II interaction on mitochondrial membrane. In our study, we aimed to increase the activity by synthesizing the novel MJ analogues with appropriate modifications. Here we report Hexokinase-2 enzyme and cell viability study results in different cancer cells. Based on the three different cancer cell lines we investigated, our novel MJ analogues proved to be more potent than the original molecule. Thus this research may provide more efficacious/novel HK-II inhibitors and may shed light to develop new anti-cancer agents.
Collapse
Affiliation(s)
- Bilgesu Onur Sucu
- Istanbul Medipol University, Vocational School of Health Services, Pharmacy Services, Kavacik Campus, Kavacik-Beykoz, Istanbul 34810, Turkey; Istanbul Medipol University, Regenerative and Restorative Medicine Research Center (REMER), Kavacik Campus, Kavacik-Beykoz, Istanbul 34810, Turkey
| | - Ozgecan Savlug Ipek
- Istanbul Medipol University, Regenerative and Restorative Medicine Research Center (REMER), Kavacik Campus, Kavacik-Beykoz, Istanbul 34810, Turkey; Yildiz Technical University, Graduate School of Natural and Applied Sciences, Department of Chemistry, Besiktas, Istanbul 34349, Turkey
| | - Sukran Ozdatli Kurtulus
- Istanbul Medipol University, Regenerative and Restorative Medicine Research Center (REMER), Kavacik Campus, Kavacik-Beykoz, Istanbul 34810, Turkey
| | - Busra Emine Yazici
- Istanbul Medipol University, Regenerative and Restorative Medicine Research Center (REMER), Kavacik Campus, Kavacik-Beykoz, Istanbul 34810, Turkey; Istanbul Medipol University, School of Medicine, Department of Medical Biology, Kavacik Campus, Kavacik-Beykoz, Istanbul 34810, Turkey
| | - Nihal Karakas
- Istanbul Medipol University, Regenerative and Restorative Medicine Research Center (REMER), Kavacik Campus, Kavacik-Beykoz, Istanbul 34810, Turkey; Istanbul Medipol University, School of Medicine, Department of Medical Biology, Kavacik Campus, Kavacik-Beykoz, Istanbul 34810, Turkey
| | - Mustafa Guzel
- Istanbul Medipol University, Regenerative and Restorative Medicine Research Center (REMER), Kavacik Campus, Kavacik-Beykoz, Istanbul 34810, Turkey; Istanbul Medipol University, International School of Medicine, Department of Medical Pharmacology, Kavacik Campus, Kavacik-Beykoz, Istanbul 34810, Turkey.
| |
Collapse
|